APA (7th ed.) Citation

Backes, F., Richardson, D., McCann, G., Salani, R., Eisenhauer, E., Fowler, J., . . . O'Malley, D. (2012). Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Gynecologic Oncology, 125, S94. https://doi.org/10.1016/j.ygyno.2011.12.226

Chicago Style (17th ed.) Citation

Backes, F., D. Richardson, G. McCann, R. Salani, E. Eisenhauer, J. Fowler, L. Copeland, D. Cohn, and D. O'Malley. "Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?" Gynecologic Oncology 125 (2012): S94. https://doi.org/10.1016/j.ygyno.2011.12.226.

MLA (9th ed.) Citation

Backes, F., et al. "Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?" Gynecologic Oncology, vol. 125, 2012, p. S94, https://doi.org/10.1016/j.ygyno.2011.12.226.